XML 33 R24.htm IDEA: XBRL DOCUMENT v3.22.2
Collaboration Agreements, License Agreement and Revenues - Astellas Agreements - Additional Information (Detail) - USD ($)
 1 Months Ended 3 Months Ended 6 Months Ended
Apr. 30, 2006
Jun. 30, 2005
Jun. 30, 2022
Mar. 31, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Dec. 31, 2021
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Total revenue     $ 29,806,000   $ 24,364,000 $ 90,633,000 $ 62,793,000  
Deferred Revenue     6,897,000     6,897,000   $ 15,857,000
Drug Product Revenue [Member]                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Total revenue     1,093,000   8,648,000 8,687,000 (168,000)  
Japan [Member]                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Transaction price, variable consideration from estimated future co-development billing           0    
Japan [Member] | Drug Product Revenue [Member]                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Total revenue       $ 9,800,000        
Europe [Member]                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Transaction price, variable consideration from estimated future co-development billing           $ 7,600,000    
Astellas Agreement [Member] | Japan [Member]                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Upfront, non-contingent and time-based payments received   $ 172,600,000            
Additional consideration based on net sales description           the low 20% range of the list price    
Aggregate consideration received excluding drug product revenue     105,100,000     $ 105,100,000    
Revenue resulting from changes to estimated variable consideration     0          
Astellas Agreement [Member] | Japan [Member] | Drug Product Revenue [Member]                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Total revenue         (2,000,000.0) $ 7,600,000 2,100,000  
Astellas Agreement [Member] | Europe [Member]                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Upfront, non-contingent and time-based payments received $ 745,000,000.0              
Additional consideration based on net sales description           low 20% range    
Aggregate consideration received excluding drug product revenue     685,000,000.0     $ 685,000,000.0    
Total revenue     1,100,000   $ 0 $ 1,100,000 $ 0  
Percentage of joint development costs committed to fund 50.00%              
Transaction price and allocated to performance obligations       $ 25,000,000.0        
Changes in revenue from changes to estimated variable consideration     $ 0